普洛药业(000739) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥2,545,629,776.07, a decrease of 0.76% compared to ¥2,565,126,389.01 in the same period last year[9] - Net profit attributable to shareholders for Q3 2023 was ¥250,278,752.86, an increase of 13.61% from ¥220,292,993.64 year-on-year[9] - The net profit after deducting non-recurring gains and losses was ¥232,777,097.18, down 4.91% from ¥244,796,455.99 in the previous year[9] - Basic and diluted earnings per share for Q3 2023 were both ¥0.2141, reflecting a growth of 13.70% compared to ¥0.1883 in the same period last year[9] - The company's operating revenue for the first nine months of 2023 reached ¥8,500,085,529.08, representing a year-on-year increase of 12.57% compared to ¥7,550,804,383.47 in the same period last year[32] - Net profit after tax amounted to ¥848,218,799.84, up from ¥655,721,307.06, reflecting a growth of 29.36%[42] - Basic and diluted earnings per share increased to ¥0.7281 from ¥0.5594, representing a rise of 30.19%[42] - The company reported a total comprehensive income attributable to shareholders of the parent company of ¥848,248,390.43, compared to ¥655,907,840.36, an increase of 29.31%[42] Assets and Liabilities - The total assets at the end of the reporting period were ¥12,619,685,652.65, representing a 5.02% increase from ¥12,016,599,023.18 at the end of the previous year[9] - The total assets increased to approximately CNY 12.62 billion, up from CNY 12.02 billion, reflecting a growth of about 5% year-over-year[19] - The total liabilities rose to CNY 6.60 billion, compared to CNY 6.50 billion, showing a growth of about 1.6%[19] - The total liabilities and equity amounted to ¥12,619,685,652.65, an increase from ¥12,016,599,023.18, showing a growth of 5.02%[39] - The equity attributable to shareholders increased to ¥6,012,837,687.80, a rise of 9.09% from ¥5,511,878,399.44 at the end of the previous year[9] Cash Flow - Cash flow from operating activities for the year-to-date was ¥848,540,440.86, a decrease of 2.55% compared to ¥870,772,728.39 in the same period last year[9] - The net cash flow from operating activities was ¥848,540,440.86, a decrease of 2.55% compared to ¥870,772,728.39 in the previous year[32] - Cash inflow from operating activities totaled ¥6,611,497,273.96, up from ¥6,008,821,887.45, reflecting a growth of 10.04%[42] - Cash and cash equivalents at the end of the period amounted to CNY 2.50 billion, an increase from CNY 2.16 billion, marking a growth of about 15.7%[27] - The net increase in cash and cash equivalents was ¥113,552,419.37, a decrease of 68.24% compared to ¥357,478,983.53 in the previous year, primarily due to increased debt repayments[32] Borrowings - Short-term borrowings increased by 39.66% to ¥786,007,326.61, primarily due to increased working capital loans[14] - Long-term borrowings decreased by 59.93% to ¥100,022,222.22, mainly due to a reduction in bank long-term loans[14] - Short-term borrowings increased to CNY 786.01 million from CNY 562.81 million, reflecting a rise of approximately 39.7%[19] Expenses - Research and development expenses increased by 19.44% to ¥483,755,349.59 from ¥405,006,874.25 year-on-year, indicating a focus on innovation and new product development[32] - The income tax expense increased by 40.88% to ¥153,380,203.03, driven by an increase in total profit[32] - The company reported a significant reduction in financial expenses, with a decrease of 29.66% to -¥88,186,800.77, primarily due to a decrease in exchange gains[32] Other Financial Metrics - The company reported a significant increase in prepayments, which rose by 98.22% to ¥435,050,546.45 due to increased material payments[14] - The company's inventory increased to ¥2,033,496,832.38 from ¥1,801,787,543.58, reflecting a 12.87% rise, which may indicate preparations for future sales[36] - The company reported a net cash outflow from investing activities of CNY 460.80 million, slightly worse than the outflow of CNY 451.38 million in the previous year[27] - The company’s deferred income tax liabilities decreased to CNY 105.47 million from CNY 118.27 million, a decline of approximately 10.8%[19] - The company’s investment income improved significantly, with a loss of -¥3,653,320.83, an 85.59% reduction from -¥25,353,904.14 year-on-year[32]